Cancer Cachexia: Innovations in Pharmacotherapy for Terminal-Stage Patients - Review of the latest reports
DOI:
https://doi.org/10.12775/JEHS.2025.77.56667Keywords
cancer cachexia, palliative care, cachexia pharmacotherapyAbstract
Introduction and purpose
Cachexia is a complex and multifactorial syndrome, which is a current, worldwide treatment challenge, and concerns most of the patients with cancer. The issue is characterized by anorexia, skeletal muscle loss, adipose tissue wasting, involuntary weight loss, malnutrition, and poor appetite due to dysfunction of metabolism and chronic, systemic inflammation. Additionally, it impacts oncological treatment and a decline in Quality of Life. The review aims to explore the latest research, innovations, and potentials in the treatment of cachexia.
Material and methods
The review was based on research of articles published from 2019 to 2024 on the PubMed database using the following keywords: cancer cachexia, palliative care, and cachexia pharmacotherapy.
Results
Anamorelin, a selective ghrelin receptor agonist showed effectiveness in weight gain and appetite improvement. Also, myostatin inhibitors protect muscles and promote their growth due to suppression of myostatin. Ponsegromab, a GDF-15 inhibitor, significantly and directly enhanced muscle mass, appetite, and quality of life, with good safety. Modern anti-inflammatory medications like momelotynib or tocilizumab, reduced the concentration of pro-inflammatory cytokines and improved quality of life, however, but posed immunosuppression risk. Pentoxifylline declined inflammation and chemotherapy toxicity, and improved body weight and survival. Cannabinoids alleviated chemotherapy-induced nausea but were ineffective for weight and quality of life.
Conclusions
Therapeutic approaches target various aspects of cachexia due to its complex pathophysiology. Anamorelin, ponsegromab, and myostatin inhibitors have clinical potential. Modern anti-inflammatory drugs and pentoxifylline offer supportive benefits. Further research is vital for developing effective and safe treatment guidelines for cancer cachexia.
References
Braha A, Albai A, Timar B, Negru Ș, Sorin S, Roman D, Popovici D. Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review. Medicina (Kaunas). 2022 Jul 21;58(7):966. PMID: 35888685; PMCID: PMC9318456.
https://doi.org/10.3390/medicina58070966
Bullock AF, Patterson MJ, Paton LW, et al. Malnutrition, sarcopenia, and cachexia: exploring prevalence, overlap, and perceptions in older adults with cancer. Eur J Clin Nutr. 2024;78(3):486-493.
https://doi.org/10.1038/s41430-024-01433-9
Yule MS, Thompson J, Leesahatsawat K, et al. Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):853-867. Epub 2024 May 23.
PMID: 38783477; PMCID: PMC11154797.
https://doi.org/10.1002/jcsm.13491
Brown LR, Sousa MS, Yule MS, et al. Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):816-852. Epub 2024 May 13. PMID: 38738581; PMCID: PMC11154800. https://doi.org/10.1002/jcsm.13478
Fujii H, Yamada Y, Iihara H, Suzuki A. The role of pharmacists in multimodal cancer cachexia care. Asia Pac J Oncol Nurs. 2023 Aug 1;10(Suppl 1):100280. PMID: 38197038; PMCID: PMC10772181.
https://doi.org/10.1016/j.apjon.2023.100280
Taniguchi J, Mikura S, da Silva Lopes K. The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis. Sci Rep. 2023 Sep 14;13(1):15257. PMID: 37709824; PMCID: PMC10502008.
https://doi.org/10.1038/s41598-023-42446-x
Nishimura A, Hamauchi S, Notsu A, et al. Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia. BMC Palliat Care. 2024 Aug 24;23(1):214. PMID: 39182074; PMCID: PMC11344333. https://doi.org/10.1186/s12904-024-01538-9
Fujita K, Akamine Y, Igarashi H, et al. Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study. Jpn J Clin Oncol. 2024 Nov 2;54(11):1165-1170. PMID: 38943560. https://doi.org/10.1093/jjco/hyae086
Egawa Y, Uchiyama M, Egoshi N, et al. Factors Associated with the Continuation of Anamorelin in Patients with Cancer-associated Cachexia: A Single-center Retrospective Study. Yakugaku Zasshi. 2024;144(7):767-774. Japanese. PMID: 38945851.
https://doi.org/10.1248/yakushi.24-00002
Tsukiyama I, Iwata T, Takeuchi T, et al. Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia. Support Care Cancer. 2023 Oct 10;31(12):621. PMID: 37815652; PMCID: PMC10564655. https://doi.org/10.1007/s00520-023-08097-4
Breen DM, Kim H, Bennett D, et al. GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. Cell Metab. 2020 Dec 1;32(6):938-950.e6. Epub 2020 Nov 17. PMID: 33207247.
https://doi.org/10.1016/j.cmet.2020.10.023
Groarke JD, Crawford J, Collins SM, et al. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1054-1061. Epub 2024 Mar 18. PMID: 38500292; PMCID: PMC11154777.
https://doi.org/10.1002/jcsm.13435
Groarke JD, Crawford J, Collins SM, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Sep 14. Epub ahead of print. PMID: 39282907.
https://doi.org/10.1056/NEJMoa2409515
Crawford J, Calle RA, Collins SM, et al. A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clin Cancer Res. 2024 Feb 1;30(3):489-497. PMID: 37982848; PMCID: PMC10831332. https://doi.org/10.1158/1078-0432.CCR-23-1631
Ojima C, Noguchi Y, Miyamoto T, et al. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia. Cancer Sci. 2020 Aug;111(8):2954-2964. Epub 2020 Jul 1. PMID: 32519375; PMCID: PMC7419029.
https://doi.org/10.1111/cas.14520
Liu D, Qiao X, Ge Z, et al. IMB0901 inhibits muscle atrophy induced by cancer cachexia through the MSTN signaling pathway. Skelet Muscle. 2019 Mar 28;9(1):8. PMID: 30922397; PMCID: PMC6437903. https://doi.org/10.1186/s13395-019-0193-2
Martin A, Gallot YS, Freyssenet D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1150-1167. Epub 2023 Mar 2. PMID: 36864755; PMCID: PMC10235899. https://doi.org/10.1002/jcsm.13073
Michiue K, Takayama K, Taniguchi A, et al. Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis. Pharmaceuticals (Basel). 2023 Mar 6;16(3):397. PMID: 36986496; PMCID: PMC10058260.
https://doi.org/10.3390/ph16030397
Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone, and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024 Dec; 161:156057. Epub 2024 Oct 30. PMID: 39481534. https://doi.org/10.1016/j.metabol.2024.156057
Hanada K, Fukasawa K, Hinata H, et al. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Sci. 2022 Oct;113(10):3547-3557. Epub 2022 Aug 6. PMID: 35849084; PMCID: PMC9530881.
https://doi.org/10.1111/cas.15491
Chrysostomou SE, Eder S, Pototschnig I, et al. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumor-bearing mice. J Cachexia Sarcopenia Muscle. 2024 Apr;15(2):562-574. Epub 2024 Feb 1. PMID: 38302863; PMCID: PMC10995265.
https://doi.org/10.1002/jcsm.13422
Chen Y, Xu W, Chen Y, et al. Renal NF-κB activation impairs uric acid homeostasis to promote tumor-associated mortality independent of wasting. Immunity. 2022 Sep 13;55(9):1594-1608.e6. Epub 2022 Aug 26. PMID: 36029766.
https://doi.org/10.1016/j.immuni.2022.07.022
Patsalos O, Dalton B, Himmerich H. Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020 Aug 31;21(17):6290. PMID: 32878032; PMCID: PMC7504579. https://doi.org/10.3390/ijms21176290
Pang X, Zhang P, Chen X, et al. Ubiquitin-proteasome pathway in skeletal muscle atrophy. Front Physiol. 2023 Nov 17; 14:1289537. PMID: 38046952; PMCID: PMC10690626.
https://doi.org/10.3389/fphys.2023.1289537
Patsalos O, Dalton B, Leppanen J, et al. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020 Apr 15; 11:481. PMID: 32351392; PMCID: PMC7174757. https://doi.org/10.3389/fphar.2020.00481
Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023 Nov 1;108(11):2919-2932. PMID: 36861402; PMCID: PMC10620561.
https://doi.org/10.3324/haematol.2022.282612
Du Y, Liu XY, Pan RL, et al. Tocilizumab for Advanced Non-Small-Cell Lung Cancer with Concomitant Cachexia: An Observational Study. J Cachexia Sarcopenia Muscle. 2024 Nov 11. Epub ahead of print. PMID: 39523982. https://doi.org/10.1002/jcsm.13638
Bowers M, Cucchiaro B, Reid J, Slee A. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: A systematic review. J Cachexia Sarcopenia Muscle. 2023 Dec;14(6):2473-2499. Epub 2023 Sep 26. PMID: 37750475; PMCID: PMC10751445.
https://doi.org/10.1002/jcsm.13327
Meirovitz A, Baider L, Peretz T, et al. Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). Tumour Biol. 2021;43(1):341-349. PMID: 34957976.
https://doi.org/10.3233/TUB-211533
Meirovitz A, Baider L, Peretz T, et al. PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics. Anticancer Res. 2022 Nov;42(11):5487-5496. PMID: 36288885. https://doi.org/10.21873/anticanres.16054
Chen H, Ishihara M, Kazahari H, Ochiai R, Tanzawa S, Honda T, Ichikawa Y, Horita N, Nagai H, Watanabe K, Seki N. Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta-analysis. Cancer Med. 2024 Sep;13(17):e70166. PMID: 39225556; PMCID: PMC11369987. https://doi.org/10.1002/cam4.70166
Hammond S, Erridge S, Mangal N, et al. The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis. Cannabis Cannabinoid Res. 2021 Dec;6(6):474-487. Epub 2021 Oct 18. PMID: 34664988; PMCID: PMC8713261.
https://doi.org/10.1089/can.2021.0048
Ceolin C, De Rui M, Ravelli A, et al. The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature. J Nutr Health Aging. 2024 Aug;28(8):100299. Epub 2024 Jun 24. PMID: 38917597. https://doi.org/10.1016/j.jnha.2024.100299
Alderman B, Hui D, Mukhopadhyay S, et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer. Support Care Cancer. 2022 Dec 16;31(1):39. PMID: 36525085. https://doi.org/10.1007/s00520-022-07480-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kinga Witowska, Karolina Sacher, Negar Hosseinnejad; Mikolaj Biskupski; Mariola Turemka, Aneta Mandziuk, Urszula Korotko, Krystyna Zabojska, Aneta Klaudia Wojtas, Aleksandra Cygnarowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 499
Number of citations: 0
